Brian Shannon on $XBI (Nov 13, 2026)
XBI's 50-day moving average is trending down; lower peaks could turn around only if it flattens. Biotech relative strength—falling less than the market—helps predict next moves but is not a reason to buy. The speaker's preferred scenario, not a prediction, is a breakdown to test or break the 200-day moving average and the year-to-date pivot, then a bear trap and rebound building for another upward push by year-end.
Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy
Jump to any passage
Biotechnology has a 50-day moving average in a downward trend. This is a group with potential , you know, it has relative strength. amazing. Amazing. Relative strength means that it does not break down with the market, i.e., it does not fall as much as the rest of the market.
It is cohesive. Well, you don't make profits from simply holding on. You profit from absolute power. Relative strength is good for predicting what might happen next, but it is not a reason to buy.
We have, as I have indicated here, these lower peaks. It appeared to have the potential to turn around if it did something like that, because the 50-day moving average would start to flatten out.
Last week I reviewed this possible scenario and it remains my preferred scenario . It's not a prediction, but I'd like everyone to start talking about this "head and shoulders" pattern .
We break down, maybe test the 200- day moving average, or even break it, then we drop to the year-to-date pivot point, and then we do this. And then , when everyone starts talking about the very obvious head and shoulders pattern, it turns out to be a trap for bears.
We go back up here and then start building for the next upward push by the end of the year. Not a prediction, but definitely my favorite scenario. I love it when we get that failed hack first.
What this channel has said about $XBI
Brian Shannon has 5 calls on this stock; only the adjacent ones are shown.